Van ECK Associates Corp Reduces Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Van ECK Associates cut its position in Edwards Lifesciences by 6.5% to 185,864 shares, valued at about $14.45 million, while institutional investors own roughly 79.46% of the stock.
• Edwards reported Q4 EPS of $0.58 (missing estimates by $0.04) and revenue of $1.57 billion (up 13.3% YoY); it set Q1 2026 guidance of $0.700–0.760 and analysts expect about 2.45 EPS for the year.
• Company insiders sold 61,718 shares in the quarter (including the CFO’s 13,000-share sale); the stock traded down 1.7% to $83.15, and the consensus analyst view is a Moderate Buy with an average price target of $96.14.

Van ECK Associates Corp decreased its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 6.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 185,864 shares of the medical research company's stock after selling 13,004 shares during the quarter. Van ECK Associates Corp's holdings in Edwards Lifesciences were worth $14,455,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Edwards Lifesciences by 0.5% during the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock valued at $5,472,147,000 after buying an additional 365,581 shares during the period. Bank of New York Mellon Corp grew its stake in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. Jennison Associates LLC grew its stake in Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the period. Geode Capital Management LLC raised its holdings in Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company's stock valued at $990,074,000 after acquiring an additional 45,555 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company's stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.7%

Shares of EW stock traded down $1.46 on Friday, reaching $83.15. 966,909 shares of the stock were exchanged, compared to its average volume of 4,545,519. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The stock has a market cap of $48.29 billion, a P/E ratio of 45.52, a price-to-earnings-growth ratio of 2.22 and a beta of 0.93. The firm has a 50 day moving average of $82.48 and a two-hundred day moving average of $81.57. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences's revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on EW shares. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the stock a "hold" rating in a research report on Wednesday, February 11th. Citigroup reissued a "buy" rating and issued a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Finally, Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a "buy" rating in a research note on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $96.14.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total value of $87,002.22. Following the completion of the sale, the vice president owned 33,934 shares of the company's stock, valued at $2,897,284.92. This represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the firm's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,371,239.08. This represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 61,718 shares of company stock worth $5,236,281. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.